AI Article Synopsis
- The study aims to update guidelines for preventing nausea and vomiting in cancer treatment using medications that usually don’t cause these symptoms.
- Experts met to discuss new information about these medications since there are more treatments that have low chances of causing nausea but not enough data on their risks.
- They concluded that patients on these low-risk treatments may need some anti-nausea medication, and if they do feel sick, specific medicines can help them feel better.
Article Abstract
Purpose: The purpose of this study is to update the guidelines for antiemetic therapy to be used with anticancer agents of low to minimal emetic potential.
Methods: Experts from the Multinational Association of Supportive Care in Cancer (MASCC) met in Perugia in 2009 to revise the MASCC antiemetic consensus guidelines. There is an increasing number of anticancer agents which are classified as being associated with a low or minimal risk of nausea and vomiting. However, the emetic potential of such agents and particularly those given as prolonged oral therapy is not well documented, and neither is the optimal antiemetic therapy.
Results: The consensus is that patients receiving anticancer therapy of low emetic potential should receive single-agent antiemetic prophylaxis such as dexamethasone, 5 hydroxytryptamine3 (5HT3) receptor antagonists, or dopamine receptor antagonists. Those receiving anticancer therapy of minimal emetic potential and who have no prior history of nausea and vomiting should not receive antiemetic prophylaxis. Those who experience nausea and vomiting subsequently can receive single-agent dexamethasone, 5HT3 receptor antagonists, or dopamine receptor antagonists.
Conclusions: More data are needed on the emetic potential and the outcome of antiemetic treatment with agents likely to fall into the low or minimal emetic potential category.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00520-010-0985-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case report: Treatment of non-medical tetrahydrocannabinol toxicosis with transmucosal cannabidiol-infused dissolving sheets in six dogs.
Front Vet Sci
December 2024
Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL, United States.
Increased cases of canine tetrahydrocannabinol (THC) toxicosis have been reported in North America in recent years. Cases are often evaluated on an emergency basis and treatment has relied upon supportive care which can be costly and prohibitive for some pet owners. The purpose of this report is to describe the clinical findings and outcomes in dogs with non-medical, presumptive THC toxicosis treated by administration of a cannibidiol (CBD)-infused transmucosal dissolving sheet.
View Article and Find Full Text PDF6-Shogaol attenuates cisplatin induced emesis by inhibiting the mtDNA-cGAS-STING signaling pathway in a rat pica model.
J Ethnopharmacol
December 2024
School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, China. Electronic address:
Ethnopharmacological Relevance: Ginger (Zingiber officinale Rosc.) is a traditional anti-emetic herb. 6-shogaol, the main active compound of ginger, is reported to possess a variety of bioactivities.
View Article and Find Full Text PDFCommunity Pharmacists' Knowledge in Managing Minor Ailments: A Focus on Childhood Gastroenteritis in Saudi Arabia Using a Simulated Patient Approach.
Healthcare (Basel)
November 2024
Department of Pharmacy Practice, College of Pharmacy, Taibah University, Madinah 41477, Saudi Arabia.
Community pharmacists are frequently approached by patients seeking health advice for minor ailments, particularly for common childhood diseases like diarrhea. Globally, approximately two million children under five years of age die each year due to diarrhea, which remains a significant health concern, especially in developing countries. The purpose of this study was to assess the skills of community pharmacists in addressing and prescribing for simple viral diarrhea in children.
View Article and Find Full Text PDFAlginate-based microencapsulation as a strategy to improve the therapeutic potential of cannabidiolic acid.
Int J Pharm
December 2024
Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Instituto de Química y Metabolismo del Fármaco (IQUIMEFA), Facultad de Farmacia y Bioquímica, Argentina; Instituto de Ciências Biológicas (ICB), Universidade Federal do Rio Grande - FURG, Rio Grande, RS, Brazil. Electronic address:
Cannabidiolic Acid (CBDA) is a promising natural compound with potent antioxidant, anti-inflammatory, and anti-emetic properties. Its antioxidant activity rivals that of vitamin E, while its anti-inflammatory effects are also remarkable. Additionally, CBDA has been shown to effectively reduce nausea and emetic attacks.
View Article and Find Full Text PDFCannabinoid Hyperemesis Syndrome (CHS) - An emerging gastrointestinal disorder and clinical challenge.
Dis Mon
December 2024
Director, Ellis Medical Toxicology Consulting, USA. Electronic address:
Nausea and vomiting are not uncommon symptoms resulting in emergency department (ED) or primary care visits. One of the emerging etiologies - Cannabinoid Hyperemesis Syndrome (CHS) remains significantly under-diagnosed, often resulting in unnecessary repeat ED visits and testing. This is in part due to lack of experience with and knowledge about CHS by health care professionals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!